(Q43300648)

English

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

scientific article published on 3 August 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 November 2017

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (English)

1 reference

Europe PubMed Central

18 November 2017

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Adriano Lazzarin

object named as

Adriano Lazzarin

3

0 references

author name string

Jeffrey L Lennox

1

1 reference

Europe PubMed Central

18 November 2017

Edwin DeJesus

2

1 reference

Europe PubMed Central

18 November 2017

Richard B Pollard

4

1 reference

Europe PubMed Central

18 November 2017

Jose Valdez Ramalho Madruga

5

1 reference

Europe PubMed Central

18 November 2017

Daniel S Berger

6

1 reference

Europe PubMed Central

18 November 2017

Jing Zhao

7

1 reference

Europe PubMed Central

18 November 2017

Xia Xu

8

1 reference

Europe PubMed Central

18 November 2017

Angela Williams-Diaz

9

1 reference

Europe PubMed Central

18 November 2017

Anthony J Rodgers

10

1 reference

Europe PubMed Central

18 November 2017

Richard J O Barnard

11

1 reference

Europe PubMed Central

18 November 2017

Michael D Miller

12

1 reference

Europe PubMed Central

18 November 2017

Mark J DiNubile

13

1 reference

Europe PubMed Central

18 November 2017

Bach-Yen Nguyen

14

1 reference

Europe PubMed Central

18 November 2017

Randi Leavitt

15

1 reference

Europe PubMed Central

18 November 2017

Peter Sklar

16

1 reference

Europe PubMed Central

18 November 2017

STARTMRK investigators

17

1 reference

Europe PubMed Central

18 November 2017

language of work or name

0 references

publication date

3 August 2009

1 reference

Europe PubMed Central

18 November 2017

1 reference

Europe PubMed Central

18 November 2017

374

1 reference

Europe PubMed Central

18 November 2017

9692

1 reference

Europe PubMed Central

18 November 2017

796-806

1 reference

Europe PubMed Central

18 November 2017

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The cost effectiveness of combination antiretroviral therapy for HIV disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Trends in antiretroviral drug resistance and clade distributions among HIV-1--infected blood donors in Sao Paulo, Brazil.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Three-class antiretroviral resistance in a patient with acute HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

The prevalence of antiretroviral drug resistance in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Routine surveillance for the detection of acute and recent HIV infections and transmission of antiretroviral resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Time trends for HIV-1 antiretroviral resistance among antiretroviral-experienced and naive pregnant women in New York City during 1991 to early 2001

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz--still first-line king?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Initial treatment for HIV infection--an embarrassment of riches

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparative analysis of two rates

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Week-12 response to therapy as a predictor of week 24, 48, and 96 outcome in patients receiving the HIV fusion inhibitor enfuvirtide in the T-20 versus Optimized Regimen Only (TORO) trials

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of neuropsychiatric side effects in an observational cohort of efavirenz- and protease inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term assessment of neuropsychiatric adverse reactions associated with efavirenz

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Switch from efavirenz to nevirapine associated with resolution of efavirenz-related neuropsychiatric adverse events and improvement in lipid profiles.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Antiretroviral therapy is associated with an atherogenic lipoprotein phenotype among HIV-1-infected men in the Multicenter AIDS Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Lack of a significant drug interaction between raltegravir and tenofovir.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2960918-1

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(09)60918-1

1 reference

Europe PubMed Central

18 November 2017

release_jp4ma4ca55dinbidruvmcx43vq

1 reference

https://api.fatcat.wiki/v0/release/jp4ma4ca55dinbidruvmcx43vq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

18 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43300648&oldid=1985765345"